Trials / Terminated
TerminatedNCT01555853
Phase I/II Study of Abraxane in Recurrent and Refractory Lymphoma
A Phase I/II Institutional Study of Abraxane in Recurrent and Refractory Lymphoma
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Washington University School of Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This phase I/II trial studies the side effects, maximum tolerated dose, and effectiveness of paclitaxel albumin-stabilized nanoparticle formulation (nab-paclitaxel) in treating patients with recurrent or refractory Hodgkin or B-cell non-Hodgkin lymphoma. More effective and well tolerated therapies are needed to treat patients with relapsed and refractory lymphomas. Nab-paclitaxel combines a chemotherapeutic agent with a protein which may increase the anticancer drug concentration in the tumor while reducing toxic effects in normal tissue and may be an effective treatment for lymphoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Abraxane |
Timeline
- Start date
- 2012-07-01
- Primary completion
- 2016-06-01
- Completion
- 2016-06-01
- First posted
- 2012-03-16
- Last updated
- 2016-12-06
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01555853. Inclusion in this directory is not an endorsement.